T2 Biosystems, a company developing direct detection products enabling superior diagnostics, announced the US Patent and Trademark Office (USPTO) has issued patent 8,344,731 (the ‘731 patent), “NMR device for the detection of analytes”. The patent describes the use of T2MR technology to directly detect physical changes within a blood sample, such as coagulation, fibrinolysis, platelet function and other hemostasis properties, as used in T2Hemostasis™ assays. T2Hemostasis is the first technology capable of rapidly characterizing key coagulation, platelet and other hematologic factors directly from whole blood on a single, compact instrument.
“This patent expands T2 Bio’s patent portfolio from direct detection of analytes within a sample to examining the physical property changes of blood, highlighting the versatility of T2MR in detecting virtually any target,” said John McDonough, president and CEO, T2 Biosystems. “T2Hemostasis will provide medical decision makers with the means to rapidly identify impaired hemostasis factors on a fast and accurate platform that is simple to operate.”
McDonough continued, “This patent, in combination with existing and recently issued patents in our portfolio, demonstrate T2 Bio’s commitment to building a broad intellectual property portfolio that protects the Company’s breakthrough T2MR technology for current and future applications.”
The ‘731 patent describes a device to measure nuclear magnetic resonance (NMR or T2MR) of protons in a blood sample for use in detecting physical changes in a blood sample. This patent brings the number of T2 Bio’s U.S.-issued patents to nine, describing the T2Dx detection device, platform assays and consumable components.
T2 Biosystems is disrupting the landscape of clinical diagnostics with T2MR™, the Company’s proprietary magnetic biosensor detector. The T2MR technology enables healthcare professionals to save lives and reduce costs by providing sensitive, accurate and rapid assay results. The Company’s products detect molecular or immunoassay targets as well as hemostasis biomarkers directly from unpurified clinical samples in hospitals, labs and physicians’ offices.